Skip to main contentSkip to footer
Statistical & Economic Modelling

Data, Statistical & Economic Analysis

We provide advanced data, statistical and economic analysis to support health technology assessment, pricing, payer and policy decisions in pharmaceutical, biotech and medtech markets.

Connect With An Access Strategist →

Analytical evidence shapes reimbursement and payer decisions

Data and analytical evidence underpin critical decisions at every stage of the market access and reimbursement pathway.

Whether quantifying comparative effectiveness, estimating economic value or forecasting budget impact, these analyses directly influence how PBAC, MSAC, payers and policymakers judge value and affordability.

  • Comparative effectiveness assessment
  • Economic value and affordability analysis
  • Budget impact and expenditure forecasting
  • HTA-ready evidence interpretation

Transforming complex data into decision-relevant evidence

Pulse Economics partners with sponsors, research organisations and health agencies to bridge the gap between technical modelling and strategic interpretation.

We ensure analysis answers key questions, supports value narratives and anticipates scrutiny from HTA bodies and payers.

Our work combines deep analytical expertise with strong health economics grounding, enabling clients to navigate complex evidence landscapes with confidence.

Analytical and modelling support in practice

Economic, Financial & Outcomes Modelling

Cost-effectiveness, cost-utility analysis, budget impact modelling and financial forecasting.

Comparative Effectiveness & Evidence Synthesis

Systematic evidence synthesis, network meta-analysis and indirect treatment comparisons.

Survival & Real-World Data Modelling

Parametric survival analysis, extrapolation strategies and RWE modelling aligned to HTA expectations.

Statistical & Predictive Analysis

Advanced statistical modelling, uncertainty analysis and predictive frameworks supporting strategy.

Scenario & Sensitivity Analysis

Threshold testing, scenario exploration and probabilistic analysis supporting payer decisions.

HTA-Ready Evidence Interpretation

Transparent analytical interpretation aligned to reimbursement and policy scrutiny.

Transparent, defensible and decision-ready analysis

01

Evaluator-Informed Interpretation

We understand how analytical outputs are reviewed and stress-tested in PBAC, MSAC and HTA environments.

02

Strategic Integration

Analytical findings are connected to pricing, reimbursement and submission strategy.

03

Transparency & Defensibility

Clear assumptions, rationale and decision logic supporting committee confidence and trust.

Turning analytical complexity into actionable insight

Decision-makers focus on uncertainty — whether around long-term outcomes, comparative value or real-world performance.

Scenario analysis and sensitivity testing

Probabilistic frameworks for uncertainty assessment

Clear visualisation and narrative interpretation

Decision-focused interpretation supporting risk mitigation and value claims

Analytical Focus Areas
Economic Modelling
High
Budget Impact
High
Comparative Evidence
High
Survival Analysis
Med
Predictive Forecasting
Med

Supporting evidence and funding decisions across the lifecycle

Pre-submission Planning & Evidence Gap Analysis

HTA Submissions Across PBS, MBS & Prescribed List

Pricing Strategy & Payer Negotiation

Policy Evaluation & Public Funding Proposals

Post-decision Monitoring & Real-world Evidence

Analytical expertise aligned to real decision environments

✓

Evaluator-level analytical insight

Deep understanding of how PBAC, MSAC and payer bodies interpret evidence.

✓

Integrated economic and strategic thinking

Connecting statistical analysis with reimbursement, pricing and HTA strategy.

✓

Practical market experience

Experience across pharmaceutical, biotech and medtech decision environments.

✓

Decision-ready analytical communication

Translating complex analysis into actionable and defensible insights.

Build evidence and analysis that support real reimbursement decisions

Align analytical rigour with HTA expectations, payer scrutiny and strategic funding objectives.

Connect With An Access Strategist →

Frequently Asked Questions

Health economic modelling turns clinical results into something MSAC or PBAC can weigh against cost, usually a cost-effectiveness or cost-utility ratio. Without it, a submission can show a product works and still be rejected, because the committee’s real question is whether the extra benefit justifies the extra cost.
They answer different questions. Cost-effectiveness analysis asks whether the extra health benefit is worth the extra cost, usually expressed as cost per QALY gained. Budget impact analysis asks what listing would cost the government in total over the next few years. PBAC and MSAC generally want both, since a technology can look cost-effective per patient and still be rejected if the total budget impact is too large.
Most trials don’t run long enough to observe every patient’s full outcome, so survival analysis is used to extrapolate beyond the trial’s follow-up. PBAC and MSAC scrutinise these extrapolations closely. The choice of parametric model can swing the result significantly, so the assumptions behind it need to hold up under scrutiny.
Usually because the assumptions underneath the model aren’t transparent enough for the committee to trust them. A structurally sound model can still be challenged on extrapolation, key inputs or how uncertainty is handled. Committees want to see the model tested under different scenarios to assess the key model drivers.
When there’s no head-to-head trial against the relevant MBS, Prescribed List or PBS comparator, a comparative effectiveness analysis (often an indirect treatment comparison or network meta-analysis) is used to estimate how the product performs against it. It’s a statistical bridge. Committees look closely at how it was built, because a weak comparison undermines the whole economic case.